In the summer, thousands of swedes have been bitten by a tick. Some of them have had the lyme disease, tbe, or any other tick-borne infections. Lyme disease is the most common tick-borne infection in Sweden, and every year it infected about 10,000 people. Between 200 and 400 people were diagnosed with tbe. It is possible that a vaccine against the tbe but not against lyme disease. What is the best way to protect yourself is to avoid tick bites and to promptly remove the tick if you still get bitten.
However, there have been a record.
the pharmaceutical companies, now known as GSK and Sanofi Pasteur, its vaccine against lyme disease. Both of which are based on the research.
“At the end of the 80s, I had, and my colleague, Alan Barbour, the idea that you would be able to make use of the protein OspA, as vaccinkandidat,” says Sven Bergström, professor in microbiology at Umeå university, sweden.
Lyme disease is caused by bacteria inside the fästingens the gastro-intestinal tract, which can be transferred to humans when the tick bites. OspA is a protein found on the surface of the borreliabakterierna. Sven Bergström, took part in the initial studies, which led to a vaccine that creates antibodies in the immune. The antibodies attack the ytproteinet OspA, which leads to that the cell membrane is destroyed and the bacteria die.
” The avdödande the efficacy of the vector. The vaccine provides a high level of antibodies in the blood. When a tick sucks the blood of the following antibodies with the killing borreliabakterierna and now, in the tick, so the virus can’t be transmitted to humans, ” says Sven Bergström.
– Sven Bergström, professor at the university of Umeå Photo: Jan Lindmark
the pharmaceutical company’s vaccine candidates have shown good efficacy and safety studies in both animals and humans, it was GSK who did it first. The vaccine Lymerix was approved in the united states by the end of 1998. Sanofi Pasteur had applied for the approval of the Imulyme.
There are several different types of borreliabakterier, and the vaccine is only effective against Borrelia burgdorferi, a variant of which is found in north America and around the world. In addition, the required multiple daily doses in the first year, and then a påfyllnadsdos on a regular basis. The level of protection was about 80 percent, and the vaccine was only approved for people aged 15-70 years of age.
in Spite of this, the company sold the vaccine, initially, for the good of the united states.
something began to of the media to report on people who have suffered from joint pain after vaccination. The u.s. drug administration (FDA) reviewed data from the studies that led to approval, and those suspected of the side effects, but did not find any evidence that there would be something wrong with the vaccine. At the same time, was a pharmaceutical company out of 121 patients, who said they had serious side-effects. Sales were three in the beginning of 2002, the company voluntarily withdrew the vaccine, citing poor market performance.
There are a lot of reasons for the interest in the Lymerix fast three. Not only was the timing is quite unfortunate, as the controversy about the two other vaccines affected the public’s attitude.
It is the first rotavirusvaccinet, Rotashield, was approved just prior to the Lymerix. However, only after a few years was the vaccine withdrawn after it proved to increase the risk of a serious tarmbiverkan.
also, the now-infamous study on an alleged link between the vaccine for measles, mumps, and rubella-and autism in children. The study had a major impact, and the number of parents choosing not to vaccinate their children. However, the link was a dud. The date the study is closed, and lots and lots of research has shown that there is no link between the MMR vaccine and autism.
in Addition, there was an article in the journal Science, which suggested that there might be a problem with the similarity between the OspA protein and a protein that is found in human beings. As it turned out later that that’s not the case, however, it was also the nail in the coffin”, says Sven Bergström.
The day a patent for Lymerix has expired, but no company has been interested in the development of a generic vaccine.
” It’s really, really weird. Six, seven years ago I was at an international borreliamöte, and it was very, very keen to get back to the vaccine, ” he said.
the dogs in the day, but not for the people. In spite of a few promising candidates in the 2010’s, has not resulted in a finished vaccine. However, it may be on the way.
The French pharmaceutical company Valneva has a vaccinkandidat in the pipeline. VLA15, which vaccinkandidaten is called, so far, it works as well as in the past borreliavaccin by creating antibodies against the ytproteinet OspA. However, it is based on a modified version of OspA, which have no similarity to the human protein.
unlike the Lymerix to be VLA15 to be able to be used on the six kinds of borreliabakterier, which is common in the northern part of the globe, not just the Borrelia burgdoferi.
on the antibiotics. However, for those who don’t get the classic ring-red-hudutslaget, the disease is difficult to diagnose. The symptoms are vague and similar to many other diseases. If left untreated, can lyme disease be spread to the nervous system and giving the remaining symptoms, in spite of that, the infection has been treated. Then it will not help with more antibiotic.
as an Additional argument in favour of a vaccine in areas where lyme disease is found, reducing health care costs; however, Valneva, in a written response to the DN.
”The american health care system is spending in each year between 712 million and $ 1.3 billion, the equivalent of 3,000 us dollars per patient to treat lyme disease. Similar to the health – care and social costs are seen in the west, that is, the region for the united states in which lyme disease is increasing the most. The benefits of a preventive vaccine for lyme disease would, in the long term, help to reduce both the personal suffering and public health costs.”
a vaccine is many years away. The process of clinical trials and the approval of new drugs is a long one. At the moment, tested the vaccine, of the 819 people in the united states and Europe. Then, further in a larger study before they can apply for an authorisation.
How the vaccine will be received in a day is very difficult to know, however, is the awareness of lyme disease, is greater today than in the 90’s. In addition, the spread of ticks over large areas, including, among other things, on the basis of the change in the climate. It’s small, but very vocal antivaccinationsrörelsen is concerned.
“Antivaccinationsrörelsen control, we never have to, but at the same time, there are many more diagnosed cases of lyme disease today than in the 90’s, and I think that the market is now more ready for a new vaccine,” says Sven Bergström.
for more information, see the Clinic, which would have the patients to make up with her lyme disease.